ACQUISITIONS and MERGERS

The proposed acquisition will establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will include CAR-T programs for solid tumors and autoimmune diseases, along with Poseida’s genetic engineering platform and related preclinical medicines.

Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. “By closing this acquisition, we’re pleased to welcome the Axonics team into Boston Scientific. The addition of the Axonics product portfolio enables us to expand into sacral neuromodulation, a high-growth adjacency for our Urology business, while bringing a comprehensive portfolio of products to patients around the world who are seeking tailored treatment options based on their life stage and incontinence severity.”

Nick Spadea-Anello, global president, Electrophysiology, Boston Scientific said, “We believe the addition of the Cortex technology complements our electrophysiology portfolio with a differentiated cardiac mapping offering to assist with complex AF cases.”

“We have maintained an advisory relationship with Kewaunee for many years and are proud to have played a role in the successful strategic acquisition of Nu Aire by Kewaunee,” added Evan Tomaskovic, Managing Partner at Carl Marks Advisors. “It is gratifying to assist a 100-year-old business complete a key acquisition of a more than 50-year-old family-owned business, fortifying the legacies of both world-class organizations.”

With the acquisition complete, ZOLL will immediately make available to customers the bellavista®, fabian®*, LTV®, and 3100 HFOV product lines alongside ZOLL’s other respiratory care offerings. For these acquired product lines, all ventilators and associated consumables, service parts, accessories, and service program offerings will continue to be sold where currently available. Existing Vyaire contact channels will remain available for use during a transition period. Customers can also contact ZOLL at ventsales@zoll.com.

Getinge paid approximately USD 253 million in cash upon completion of the acquisition, on a cash and debt free basis. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed USD 224 million in aggregate. The initial payout related to the acquisition has been financed through a bridge loan provided by SEB. The acquisition is expected to have a slightly negative impact on Getinge’s adjusted earnings per share in 2024. Getinge anticipates a positive contribution on adjusted earnings per share starting in 2028.